The DOI matches its Crossref record; 210 of the 210 references it cites were found in a registry or an index.
Targeting Protein–Protein Interactions for Therapeutic Intervention: A Challenge for the Future
Abstract
BACKGROUND: Over the last two decades, an increasing research effort in academia and industry has focused on the modulation (both inhibition and stabilization) of protein-protein interactions (PPIs) in order to develop novel therapeutic approaches and target-selective agents in drug discovery. DISCUSSION: The diversity and complexity of highly dynamic systems such as PPIs present many challenges for the identification of drug-like molecules with the ability to modulate the PPI with the necessary selectivity and potency. In this review, a number of these strategies will be presented along with a critical overview of the challenges and potential solutions relating to the exploitation of PPIs as molecular targets. CONCLUSIONS: Both traditional drug discovery approaches and some more recently developed innovative strategies have already provided valuable tools for the discovery of PPI modulators, and a number of successful examples have highlighted the potential of targeting PPIs for therapeutic intervention, especially in the oncology area.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Drug Delivery Systems: Entering the Mainstream
Allen, T. M., & Cullis, P. R. (2004) · Science · doi:10.1126/science.1095833 · Cited by 4,552
The Bcl2 family: regulators of the cellular life-or-death switch
Cory, S., & Adams, J. M. (2002) · Nature Reviews Cancer · doi:10.1038/nrc883 · Cited by 4,032
Bromberg, J. F., Wrzeszczynska, M. H., Devgan, G., Zhao, Y., Pestell, R. G., Albanese, C., & Darnell, J. E. (1999) · Cell · doi:10.1016/s0092-8674(00)81959-5 · Cited by 2,790
The evolving role of natural products in drug discovery
Koehn, F. E., & Carter, G. T. (2005) · Nature Reviews Drug Discovery · doi:10.1038/nrd1657 · Cited by 2,572
A Hot Spot of Binding Energy in a Hormone-Receptor Interface
Clackson, T., & Wells, J. A. (1995) · Science · doi:10.1126/science.7529940 · Cited by 1,983
Reaching for high-hanging fruit in drug discovery at protein–protein interfaces
Wells, J. A., & McClendon, C. L. (2007) · Nature · doi:10.1038/nature06526 · Cited by 1,960
Restoration of p53 function leads to tumour regression in vivo
Ventura, A., Kirsch, D. G., McLaughlin, M. E., Tuveson, D. A., Grimm, J., Lintault, L., Newman, J., Reczek, E. E., Weissleder, R., & Jacks, T. (2007) · Nature · doi:10.1038/nature05541 · Cited by 1,820
Dundas, J., Ouyang, Z., Tseng, J., Binkowski, A., Turpaz, Y., & Liang, J. (2006) · Nucleic Acids Research · doi:10.1093/nar/gkl282 · Cited by 1,725
Letai, A., Bassik, M. C., Walensky, L. D., Sorcinelli, M. D., Weiler, S., & Korsmeyer, S. J. (2002) · Cancer Cell · doi:10.1016/s1535-6108(02)00127-7 · Cited by 1,677
Activation of Apoptosis in Vivo by a Hydrocarbon-Stapled BH3 Helix
Walensky, L. D., Kung, A. L., Escher, I., Malia, T. J., Barbuto, S., Wright, R. D., Wagner, G., Verdine, G. L., & Korsmeyer, S. J. (2004) · Science · doi:10.1126/science.1099191 · Cited by 1,349
Targeting Apoptosis Pathways in Cancer Therapy
Ghobrial, I. M., Witzig, T. E., & Adjei, A. A. (2005) · CA: A Cancer Journal for Clinicians · doi:10.3322/canjclin.55.3.178 · Cited by 1,330
van Delft, M. F., Wei, A. H., Mason, K. D., Vandenberg, C. J., Chen, L., Czabotar, P. E., Willis, S. N., Scott, C. L., Day, C. L., Cory, S., et al. (2006) · Cancer Cell · doi:10.1016/j.ccr.2006.08.027 · Cited by 1,240
Drug development from marine natural products
Molinski, T. F., Dalisay, D. S., Lievens, S. L., & Saludes, J. P. (2009) · Nature Reviews Drug Discovery · doi:10.1038/nrd2487 · Cited by 1,186
Olefin‐Metathesis Catalysts for the Preparation of Molecules and Materials (Nobel Lecture)
Grubbs, R. H. (2006) · Angewandte Chemie International Edition · doi:10.1002/anie.200600680 · Cited by 1,147
Transcriptional regulation and transformation by Myc proteins
Adhikary, S., & Eilers, M. (2005) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm1703 · Cited by 1,131
Promoting apoptosis as a strategy for cancer drug discovery
Fesik, S. W. (2005) · Nature Reviews Cancer · doi:10.1038/nrc1736 · Cited by 1,098
Schafmeister, C. E., Po, J., & Verdine, G. L. (2000) · Journal of the American Chemical Society · doi:10.1021/ja000563a · Cited by 1,037
p53 and Human Cancer: The First Ten Thousand Mutations
(1999) · Advances in Cancer Research · doi:10.1016/s0065-230x(08)60785-x · Cited by 986
Hypoxia-Inducible Factor 1 (HIF-1) Pathway
Semenza, G. L. (2007) · Science's STKE · doi:10.1126/stke.4072007cm8 · Cited by 945
Structure of the FKBP12-Rapamycin Complex Interacting with Binding Domain of Human FRAP
Choi, J., Chen, J., Schreiber, S. L., & Clardy, J. (1996) · Science · doi:10.1126/science.273.5272.239 · Cited by 929
X-ray structure of calcineurin inhibited by the immunophilin-immunosuppressant FKBP12-FK506 complex
Griffith, J. P., Kim, J. L., Kim, E. E., Sintchak, M. D., Thomson, J. A., Fitzgibbon, M. J., Fleming, M. A., Caron, P. R., Hsiao, K., & Navia, M. A. (1995) · Cell · doi:10.1016/0092-8674(95)90439-5 · Cited by 834
Ideker, T., & Sharan, R. (2008) · Genome Research · doi:10.1101/gr.071852.107 · Cited by 817
Specificity in Signal Transduction
Pawson, T. (2004) · Cell · doi:10.1016/s0092-8674(03)01077-8 · Cited by 816
Three-dimensional structure of the Stat3β homodimer bound to DNA
Becker, S., Groner, B., & Müller, C. W. (1998) · Nature · doi:10.1038/28101 · Cited by 788
Protein–protein interactions define specificity in signal transduction
Pawson, T., & Nash, P. (2000) · Genes & Development · doi:10.1101/gad.14.9.1027 · Cited by 780
Hot spots—A review of the protein–protein interface determinant amino‐acid residues
Moreira, I. S., Fernandes, P. A., & Ramos, M. J. (2007) · Proteins: Structure, Function, and Bioinformatics · doi:10.1002/prot.21396 · Cited by 760
Siddiquee, K., Zhang, S., Guida, W. C., Blaskovich, M. A., Greedy, B., Lawrence, H. R., Yip, M. L. R., Jove, R., McLaughlin, M. M., Lawrence, N. J., et al. (2007) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0609757104 · Cited by 736
Hypoxia: A key regulator of angiogenesis in cancer
Liao, D., & Johnson, R. S. (2007) · Cancer and Metastasis Reviews · doi:10.1007/s10555-007-9066-y · Cited by 721
Natural Products as Leads to Potential Drugs: An Old Process or the New Hope for Drug Discovery?
Newman, D. J. (2008) · Journal of Medicinal Chemistry · doi:10.1021/jm0704090 · Cited by 716
Small-molecule MDM2 antagonists reveal aberrant p53 signaling in cancer: implications for therapy
Tovar, C., Rosinski, J., Filipovic, Z., Higgins, B., Kolinsky, K., Hilton, H., Zhao, X., Vu, B. T., Qing, W., Packman, K., et al. (2006) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0507493103 · Cited by 708
Principles of Protein−Protein Interactions: What are the Preferred Ways For Proteins To Interact?
Keskin, O., Gursoy, A., Ma, B., & Nussinov, R. (2008) · Chemical Reviews · doi:10.1021/cr040409x · Cited by 697
Structure-based maximal affinity model predicts small-molecule druggability
Cheng, A. C., Coleman, R. G., Smyth, K. T., Cao, Q., Soulard, P., Caffrey, D. R., Salzberg, A. C., & Huang, E. S. (2007) · Nature Biotechnology · doi:10.1038/nbt1273 · Cited by 695
Allosteric regulation and catalysis emerge via a common route
Goodey, N. M., & Benkovic, S. J. (2008) · Nature Chemical Biology · doi:10.1038/nchembio.98 · Cited by 667
Shangary, S., Qin, D., McEachern, D., Liu, M., Miller, R. S., Qiu, S., Nikolovska-Coleska, Z., Ding, K., Wang, G., Chen, J., et al. (2008) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0708917105 · Cited by 660
The impact of natural products upon modern drug discovery
Ganesan, A. (2008) · Current Opinion in Chemical Biology · doi:10.1016/j.cbpa.2008.03.016 · Cited by 646
HIF-1 as a target for drug development
Giaccia, A., Siim, B. G., & Johnson, R. S. (2003) · Nature Reviews Drug Discovery · doi:10.1038/nrd1199 · Cited by 631
Shangary, S., & Wang, S. (2009) · Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev.pharmtox.48.113006.094723 · Cited by 623
BCL-2 family antagonists for cancer therapy
Lessene, G., Czabotar, P. E., & Colman, P. M. (2008) · Nature Reviews Drug Discovery · doi:10.1038/nrd2658 · Cited by 621
Modeling the Therapeutic Efficacy of p53 Restoration in Tumors
Martins, C. P., Brown-Swigart, L., & Evan, G. I. (2006) · Cell · doi:10.1016/j.cell.2006.12.007 · Cited by 600
The nuclear receptor superfamily
Robinson-Rechavi, M., Garcia, H. E., & Laudet, V. (2003) · Journal of Cell Science · doi:10.1242/jcs.00247 · Cited by 587
Reactivation of the p53 Tumor Suppressor Pathway by a Stapled p53 Peptide
Bernal, F., Tyler, A. F., Korsmeyer, S. J., Walensky, L. D., & Verdine, G. L. (2007) · Journal of the American Chemical Society · doi:10.1021/ja0693587 · Cited by 556
Peptidomimetics, a synthetic tool of drug discovery
Vagner, J., Qu, H., & Hruby, V. J. (2008) · Current Opinion in Chemical Biology · doi:10.1016/j.cbpa.2008.03.009 · Cited by 538
MDM2 inhibitors for cancer therapy
Vassilev, L. T. (2007) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2006.11.002 · Cited by 532
Keskin, O., Ma, B., & Nussinov, R. (2005) · Journal of Molecular Biology · doi:10.1016/j.jmb.2004.10.077 · Cited by 519
Kowalski, R. J., Giannakakou, P., & Hamel, E. (1997) · Journal of Biological Chemistry · doi:10.1074/jbc.272.4.2534 · Cited by 511
Echinomycin, a small-molecule inhibitor of hypoxia-inducible factor-1 DNA-binding activity.
Kong, D., Park, E. J., Stephen, A. G., Calvani, M., Cardellina, J. H., Monks, A., Fisher, R. J., Shoemaker, R. H., & Melillo, G. (2005) · Cancer Research · doi:10.1158/0008-5472.can-05-1235 · Cited by 508
Song, H., Wang, R., Wang, S., & Lin, J. (2005) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0409894102 · Cited by 504
Small molecule blockade of transcriptional coactivation of the hypoxia-inducible factor pathway
Kung, A. L., Zabludoff, S. D., France, D. S., Freedman, S. J., Tanner, E. A., Vieira, A., Cornell-Kennon, S., Lee, J., Wang, B., Wang, J., et al. (2004) · Cancer Cell · doi:10.1016/j.ccr.2004.06.009 · Cited by 480
Kamura, T., Maenaka, K., Kotoshiba, S., Matsumoto, M., Kohda, D., Conaway, R. C., Conaway, J. W., & Nakayama, K. I. (2004) · Genes & Development · doi:10.1101/gad.1252404 · Cited by 477
Brefeldin A Acts to Stabilize an Abortive ARF–GDP–Sec7 Domain Protein Complex
Peyroche, A., Antonny, B., Robineau, S., Acker, J., Cherfils, J., & Jackson, C. L. (1999) · Molecular Cell · doi:10.1016/s1097-2765(00)80455-4 · Cited by 453
Allostery: Absence of a change in shape does not imply that allostery is not at play
Tsai, C.-J., del Sol, A., & Nussinov, R. (2008) · Journal of Molecular Biology · doi:10.1016/j.jmb.2008.02.034 · Cited by 453
Strategies for Targeting Protein–Protein Interactions With Synthetic Agents
Yin, H., & Hamilton, A. D. (2005) · Angewandte Chemie International Edition · doi:10.1002/anie.200461786 · Cited by 453
The design of drugs for HIV and HCV
Clercq, E. D. (2007) · Nature Reviews Drug Discovery · doi:10.1038/nrd2424 · Cited by 430
Drug discovery beyond the ‘rule-of-five’
Zhang, M.-Q., & Wilkinson, B. (2007) · Current Opinion in Biotechnology · doi:10.1016/j.copbio.2007.10.005 · Cited by 418
von der Lehr, N., Johansson, S., Wu, S., Bahram, F., Castell, A., Cetinkaya, C., Hydbring, P., Weidung, I., Nakayama, K., Nakayama, K. I., et al. (2003) · Molecular Cell · doi:10.1016/s1097-2765(03)00193-x · Cited by 408
Crystal Structure of a β-Catenin/Tcf Complex
Graham, T. A., Weaver, C., Mao, F., Kimelman, D., & Xu, W. (2000) · Cell · doi:10.1016/s0092-8674(00)00192-6 · Cited by 405
Hudson, P. J., & Souriau, C. (2003) · Nature Medicine · doi:10.1038/nm0103-129 · Cited by 398
A Stapled BID BH3 Helix Directly Binds and Activates BAX
Walensky, L. D., Pitter, K., Morash, J., Oh, K. J., Barbuto, S., Fisher, J., Smith, E., Verdine, G. L., & Korsmeyer, S. J. (2006) · Molecular Cell · doi:10.1016/j.molcel.2006.08.020 · Cited by 383
Protein–protein interactions in human disease
RYAN, D., & MATTHEWS, J. (2005) · Current Opinion in Structural Biology · doi:10.1016/j.sbi.2005.06.001 · Cited by 375
Verdine, G. L., & Walensky, L. D. (2007) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-07-2184 · Cited by 361
Bcl-2 inhibitors: small molecules with a big impact on cancer therapy
Vogler, M., Dinsdale, D., Dyer, M. J. S., & Cohen, G. M. (2009) · Cell Death & Differentiation · doi:10.1038/cdd.2008.137 · Cited by 357
Extended disordered proteins: targeting function with less scaffold
Gunasekaran, K., Tsai, C.-J., Kumar, S., Zanuy, D., & Nussinov, R. (2003) · Trends in Biochemical Sciences · doi:10.1016/s0968-0004(03)00003-3 · Cited by 338
Berg, T., Cohen, S. B., Desharnais, J., Sonderegger, C., Maslyar, D. J., Goldberg, J., Boger, D. L., & Vogt, P. K. (2002) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.062036999 · Cited by 326
Validating Stat3 in cancer therapy
Darnell, J. E. (2005) · Nature Medicine · doi:10.1038/nm0605-595 · Cited by 307
Studies Leading to Potent, Dual Inhibitors of Bcl-2 and Bcl-xL
Bruncko, M., Oost, T. K., Belli, B. A., Ding, H., Joseph, M. K., Kunzer, A., Martineau, D., McClellan, W. J., Mitten, M., Ng, S.-C., et al. (2007) · Journal of Medicinal Chemistry · doi:10.1021/jm061152t · Cited by 304
Tumor hypoxia and cancer progression
Zhou, J., Schmid, T., Schnitzer, S., & Brüne, B. (2006) · Cancer Letters · doi:10.1016/j.canlet.2005.05.028 · Cited by 302
Park, C.-M., Bruncko, M., Adickes, J., Bauch, J., Ding, H., Kunzer, A., Marsh, K. C., Nimmer, P., Shoemaker, A. R., Song, X., et al. (2008) · Journal of Medicinal Chemistry · doi:10.1021/jm800669s · Cited by 300
Progress in Modeling of Protein Structures and Interactions.
Schueler-Furman, O., Wang, C., Bradley, P., Misura, K., & Baker, D. (2005) · Science · doi:10.1126/science.1112160 · Cited by 294
Modulation of Protein–Protein Interactions with Small Organic Molecules
Berg, T. (2003) · Angewandte Chemie International Edition · doi:10.1002/anie.200200558 · Cited by 292
Inhibition of Protein−Protein Association by Small Molecules: Approaches and Progress
Toogood, P. L. (2002) · Journal of Medicinal Chemistry · doi:10.1021/jm010468s · Cited by 281
Targeting Stat3 in cancer therapy
Jing, N., & Tweardy, D. J. (2005) · Anti-Cancer Drugs · doi:10.1097/00001813-200507000-00002 · Cited by 278
Rishton, G. M. (2008) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2008.02.007 · Cited by 276
Computational alanine scanning mutagenesis—An improved methodological approach
Moreira, I. S., Fernandes, P. A., & Ramos, M. J. (2007) · Journal of Computational Chemistry · doi:10.1002/jcc.20566 · Cited by 273
Friedler, A., Hansson, L. O., Veprintsev, D. B., Freund, S. M. V., Rippin, T. M., Nikolova, P. V., Proctor, M. R., Rüdiger, S., & Fersht, A. R. (2002) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.241629998 · Cited by 268
Rayburn, E., Zhang, R., He, J., & Wang, H. (2005) · Current Cancer Drug Targets · doi:10.2174/1568009053332636 · Cited by 265
Kowalski, R. J., Giannakakou, P., Gunasekera, S. P., Longley, R. E., Day, B. W., & Hamel, E. (1997) · Molecular Pharmacology · doi:10.1124/mol.52.4.613 · Cited by 262
Huang, M.-J., Cheng, Y.-C., Liu, C.-R., Lin, S., & Liu, H. E. (2006) · Experimental Hematology · doi:10.1016/j.exphem.2006.06.019 · Cited by 259
Patgiri, A., Jochim, A. L., & Arora, P. S. (2008) · Accounts of Chemical Research · doi:10.1021/ar700264k · Cited by 251
Synthetic non-peptide mimetics of α-helices
Davis, J. M., Tsou, L. K., & Hamilton, A. D. (2007) · Chem. Soc. Rev. · doi:10.1039/b608043j · Cited by 240
A Highly Stable Short α-Helix Constrained by a Main-Chain Hydrogen-Bond Surrogate
Chapman, R. N., Dimartino, G., & Arora, P. S. (2004) · Journal of the American Chemical Society · doi:10.1021/ja0466659 · Cited by 228
Synthesis of Natural‐Product‐Like Molecules with Over Eighty Distinct Scaffolds
Morton, D., Leach, S., Cordier, C., Warriner, S., & Nelson, A. (2009) · Angewandte Chemie International Edition · doi:10.1002/anie.200804486 · Cited by 224
Design and properties of a Myc derivative that efficiently homodimerizes
Soucek, L., Helmer-Citterich, M., Sacco, A., Jucker, R., Cesareni, G., & Nasi, S. (1998) · Oncogene · doi:10.1038/sj.onc.1202199 · Cited by 221
Loughlin, W. A., Tyndall, J. D. A., Glenn, M. P., & Fairlie, D. P. (2004) · Chemical Reviews · doi:10.1021/cr040648k · Cited by 220
Cordier, C., Morton, D., Murrison, S., Nelson, A., & O'Leary-Steele, C. (2008) · Natural Product Reports · doi:10.1039/b706296f · Cited by 215
Wnt and beyond Wnt: Multiple mechanisms control the transcriptional property of β-catenin
Jin, T., George Fantus, I., & Sun, J. (2008) · Cellular Signalling · doi:10.1016/j.cellsig.2008.04.014 · Cited by 215
A Cell-penetrating Helical Peptide as a Potential HIV-1 Inhibitor
Zhang, H., Zhao, Q., Bhattacharya, S., Waheed, A. A., Tong, X., Hong, A., Heck, S., Curreli, F., Goger, M., Cowburn, D., et al. (2008) · Journal of Molecular Biology · doi:10.1016/j.jmb.2008.02.066 · Cited by 215
Li, X., Keskin, O., Ma, B., Nussinov, R., & Liang, J. (2004) · Journal of Molecular Biology · doi:10.1016/j.jmb.2004.09.051 · Cited by 215
Mining and engineering natural-product biosynthetic pathways
Wilkinson, B., & Micklefield, J. (2007) · Nature Chemical Biology · doi:10.1038/nchembio.2007.7 · Cited by 208
Fluorescent biosensors of protein function
VanEngelenburg, S. B., & Palmer, A. E. (2008) · Current Opinion in Chemical Biology · doi:10.1016/j.cbpa.2008.01.020 · Cited by 208
Protein–protein interactions as targets for small molecule drug discovery
Fry, D. C. (2006) · Peptide Science · doi:10.1002/bip.20608 · Cited by 206
Structure of a human Tcf4-beta-catenin complex.
Poy, F., Lepourcelet, M., Shivdasani, R. A., & Eck, M. J. (2001) · Nature Structural Biology · doi:10.1038/nsb720 · Cited by 205
McMillan, K., Adler, M., Auld, D. S., Baldwin, J. J., Blasko, E., Browne, L. J., Chelsky, D., Davey, D., Dolle, R. E., Eagen, K. A., et al. (2000) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.97.4.1506 · Cited by 201
Terphenyl-Based Bak BH3 α-Helical Proteomimetics as Low-Molecular-Weight Antagonists of Bcl-x L
Yin, H., Lee, G.-I., Sedey, K. A., Kutzki, O., Park, H. S., Orner, B. P., Ernst, J. T., Wang, H.-G., Sebti, S. M., & Hamilton, A. D. (2005) · Journal of the American Chemical Society · doi:10.1021/ja050122x · Cited by 198
Role of Stat3 in suppressing anti-tumor immunity
Kortylewski, M., & Yu, H. (2008) · Current Opinion in Immunology · doi:10.1016/j.coi.2008.03.010 · Cited by 196
Gonzalez-Ruiz, D., & Gohlke, H. (2006) · Current Medicinal Chemistry · doi:10.2174/092986706778201530 · Cited by 190
Improved low molecular weight Myc-Max inhibitors
Wang, H., Hammoudeh, D. I., Follis, A. V., Reese, B. E., Lazo, J. S., Metallo, S. J., & Prochownik, E. V. (2007) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-07-0005 · Cited by 190
SPR-based Fragment Screening: Advantages and Applications
Neumann, T., Junker, H.-D., Schmidt, K., & Sekul, R. (2007) · Current Topics in Medicinal Chemistry · doi:10.2174/156802607782341073 · Cited by 189
Rational design of a CD4 mimic that inhibits HIV-1 entry and exposes cryptic neutralization epitopes
Martin, L., Stricher, F., Missé, D., Sironi, F., Pugnière, M., Barthe, P., Prado-Gotor, R., Freulon, I., Magne, X., Roumestand, C., et al. (2003) · Nature Biotechnology · doi:10.1038/nbt768 · Cited by 188
Siddiquee, K. A. Z., Gunning, P. T., Glenn, M., Katt, W. P., Zhang, S., Schroeck, C., Sebti, S. M., Jove, R., Hamilton, A. D., & Turkson, J. (2007) · ACS Chemical Biology · doi:10.1021/cb7001973 · Cited by 187
Targeting protein–protein interactions: Lessons from p53/MDM2
Murray, J. K., & Gellman, S. H. (2007) · Peptide Science · doi:10.1002/bip.20741 · Cited by 186
Follis, A. V., Hammoudeh, D. I., Wang, H., Prochownik, E. V., & Metallo, S. J. (2008) · Chemistry & Biology · doi:10.1016/j.chembiol.2008.09.011 · Cited by 183
Trosset, J., Dalvit, C., Knapp, S., Fasolini, M., Veronesi, M., Mantegani, S., Gianellini, L. M., Catana, C., Sundström, M., Stouten, P. F. W., et al. (2006) · Proteins: Structure, Function, and Bioinformatics · doi:10.1002/prot.20955 · Cited by 181
Klampfer, L. (2006) · Current Cancer Drug Targets · doi:10.2174/156800906776056491 · Cited by 171
Emerging classes of protein–protein interaction inhibitors and new tools for their development
Pagliaro, L., Felding, J., Audouze, K., Nielsen, S. J., Terry, R. B., Krog-Jensen, C., & Butcher, S. (2004) · Current Opinion in Chemical Biology · doi:10.1016/j.cbpa.2004.06.006 · Cited by 168
Burgoyne, N. J., & Jackson, R. M. (2006) · Bioinformatics · doi:10.1093/bioinformatics/btl079 · Cited by 166
Inhibiting Hypoxia-Inducible Factor 1 for Cancer Therapy
Melillo, G. (2006) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-06-0235 · Cited by 166
Design and Applications of Bifunctional Small Molecules: Why Two Heads Are Better Than One
Corson, T. W., Aberle, N., & Crews, C. M. (2008) · ACS Chemical Biology · doi:10.1021/cb8001792 · Cited by 165
Bullock, A. N., Debreczeni, J. É., Edwards, A. M., Sundström, M., & Knapp, S. (2006) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0601638103 · Cited by 165
Between a rock and a hard place?
Whitty, A., & Kumaravel, G. (2006) · Nature Chemical Biology · doi:10.1038/nchembio0306-112 · Cited by 162
Targeting protein–protein interactions for cancer therapy
Fry, D. C., & Vassilev, L. T. (2005) · Journal of Molecular Medicine · doi:10.1007/s00109-005-0705-x · Cited by 159
Villunger, A., Scott, C. L., Bouillet, P., & Strasser, A. (2003) · Blood · doi:10.1182/blood-2002-07-2132 · Cited by 158
Vita, C., Drakopoulou, E., Vizzavona, J., Rochette, S., Martin, L., Ménèz, A., Roumestand, C., Yang, Y., Ylisastigui, L., Benjouad, A., et al. (1999) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.96.23.13091 · Cited by 155
Scorpion toxins as natural scaffolds for protein engineering.
Vita, C., Roumestand, C., Toma, F., et al. (1995) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.92.14.6404 · Cited by 154
Selective Inhibition of c-Myc/Max Dimerization and DNA Binding by Small Molecules
Kiessling, A., Sperl, B., Hollis, A., Eick, D., & Berg, T. (2006) · Chemistry & Biology · doi:10.1016/j.chembiol.2006.05.011 · Cited by 153
Turkson, J., Zhang, S., Mora, L. B., Burns, A. C., Sebti, S. M., & Jove, R. (2005) · Journal of Biological Chemistry · doi:10.1074/jbc.m502694200 · Cited by 153
Biomolecular Interaction Analysis in Drug Discovery Using Surface Plasmon Resonance Technology
Huber, W., & Mueller, F. (2006) · Current Pharmaceutical Design · doi:10.2174/138161206778743600 · Cited by 151
Similar Binding Sites and Different Partners: Implications to Shared Proteins in Cellular Pathways
Keskin, O., & Nussinov, R. (2007) · Structure · doi:10.1016/j.str.2007.01.007 · Cited by 150
Myc Goes Global: New Tricks for an Old Oncogene
Knoepfler, P. S. (2007) · Cancer Research · doi:10.1158/0008-5472.can-07-0426 · Cited by 147
Exploring New Chemical Space by Stereocontrolled Diversity-Oriented Synthesis
Arya, P., Joseph, R., Gan, Z., & Rakić, B. (2005) · Chemistry & Biology · doi:10.1016/j.chembiol.2005.01.011 · Cited by 142
Mutational spectrum of p53 mutations in primary breast and ovarian tumors
Feki, A., & Irminger-Finger, I. (2004) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2004.07.002 · Cited by 139
Landon, M. R., Lancia, D. R., Yu, J., Thiel, S., & Vajda, S. (2007) · Journal of Medicinal Chemistry · doi:10.1021/jm061134b · Cited by 135
The MYC Oncogene as a Cancer Drug Target
Hermeking, H. (2003) · Current Cancer Drug Targets · doi:10.2174/1568009033481949 · Cited by 133
Drugs Targeting Protein–Protein Interactions
Chêne, P. (2006) · ChemMedChem · doi:10.1002/cmdc.200600004 · Cited by 132
Wnt signaling and cancer development: therapeutic implication.
Paul, S., & Dey, A. (2008) · PubMed · Cited by 132
Small molecular weight protein–protein interaction antagonists—an insurmountable challenge?
Dömling, A. S. S. (2008) · Current Opinion in Chemical Biology · doi:10.1016/j.cbpa.2008.04.603 · Cited by 130
Design and synthesis of α-helical peptides and mimetics
Garner, J., & Harding, M. M. (2007) · Organic & Biomolecular Chemistry · doi:10.1039/b710425a · Cited by 129
Design and Structure of Peptide and Peptidomimetic Antagonists of Protein- Protein Interaction
Sillerud, L. O., & Larson, R. A. (2005) · Current Protein and Peptide Science · doi:10.2174/1389203053545462 · Cited by 129
Wang, W., Takimoto, R., Rastinejad, F., & El-Deiry, W. S. (2003) · Molecular and Cellular Biology · doi:10.1128/mcb.23.6.2171-2181.2003 · Cited by 126
Non‐peptidic small molecule inhibitors against Bcl‐2 for cancer therapy
Azmi, A. S., & Mohammad, R. M. (2008) · Journal of Cellular Physiology · doi:10.1002/jcp.21567 · Cited by 123
Initial testing (stage 1) of the BH3 mimetic ABT‐263 by the pediatric preclinical testing program
Lock, R. B., Carol, H., Houghton, P. J., Morton, C. L., Kolb, E. A., Gorlick, R. G., Reynolds, C. P., Maris, J. M., Keir, S. T., Wu, J., et al. (2007) · Pediatric Blood & Cancer · doi:10.1002/pbc.21433 · Cited by 123
Guo, J., Parise, R. A., Joseph, E., Egorin, M. J., Lazo, J. S., Prochownik, E. V., & Eiseman, J. L. (2008) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-008-0774-y · Cited by 123
Kohl, T. M., Hellinger, C., Ahmed, F., Buske, C., Hiddemann, W., Bohlander, S. K., & Spiekermann, K. (2007) · Leukemia · doi:10.1038/sj.leu.2404776 · Cited by 119
Hypoxia, drug therapy and toxicity
Lee, K., Roth, R. A., & LaPres, J. J. (2006) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2006.08.001 · Cited by 119
Gorczynski, M. J., Grembecka, J. E., Zhou, Y., Kong, Y., Roudaia, L., Douvas, M. G., Newman, M. N., Bielnicka, I., Baber, G. B., Corpora, T., et al. (2007) · Chemistry & Biology · doi:10.1016/j.chembiol.2007.09.006 · Cited by 116
The magic of the hypoxia-signaling cascade
Benizri, E. I., Ginouvès, A., & Berra, E. (2008) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-008-7472-0 · Cited by 112
Interaction of the TAZ1 Domain of the CREB-Binding Protein with the Activation Domain of CITED2
Guzman, R. N. D., Martinez‐Yamout, M. A., Dyson, H. J., & Wright, P. E. (2004) · Journal of Biological Chemistry · doi:10.1074/jbc.m310348200 · Cited by 109
Disruption of protein–protein interactions: Towards new targets for chemotherapy
Loregian, A., & Palù, G. (2005) · Journal of Cellular Physiology · doi:10.1002/jcp.20356 · Cited by 108
Design and Evolution of a Miniature Bcl-2 Binding Protein
Chin, J. W., & Schepartz, A. (2001) · Angewandte Chemie International Edition · doi:10.1002/1521-3773(20011015)40:20<3806::aid-anie3806>3.0.co;2-b · Cited by 108
Minimally Cationic Cell-Permeable Miniature Proteins via α-Helical Arginine Display
Smith, B. A., Daniels, D. S., Coplin, A., Jordan, G. E., McGregor, L. M., & Schepartz, A. (2008) · Journal of the American Chemical Society · doi:10.1021/ja800074v · Cited by 102
NMR experiments for lead generation in drug discovery
Peng, J. W., Moore, J. M., & Abdul-Manan, N. (2004) · Progress in Nuclear Magnetic Resonance Spectroscopy · doi:10.1016/j.pnmrs.2004.03.001 · Cited by 97
The Chemical Biology of Apoptosis
Huang, Z. (2002) · Chemistry & Biology · doi:10.1016/s1074-5521(02)00247-8 · Cited by 97
Molecular Recognition of Protein Surfaces: High Affinity Ligands for the CBP KIX Domain
Rutledge, S. E., Volkman, H. M., & Schepartz, A. (2003) · Journal of the American Chemical Society · doi:10.1021/ja034508o · Cited by 94
Skeletal diversity construction via a branching synthetic strategy
Wyatt, E. E., Fergus, S., Galloway, W. R. J. D., Bender, A., Fox, D. J., Plowright, A. T., Jessiman, A. S., Welch, M., & Spring, D. R. (2006) · Chemical Communications · doi:10.1039/b607710b · Cited by 94
A credit-card library approach for disrupting protein–protein interactions
Xu, Y., Shi, J., Yamamoto, N., Moss, J. A., Vogt, P. K., & Janda, K. D. (2006) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2005.11.052 · Cited by 93
Atomic Structure of a Short α-Helix Stabilized by a Main Chain Hydrogen-Bond Surrogate
Liu, J., Wang, D., Zheng, Q., Lu, M., & Arora, P. S. (2008) · Journal of the American Chemical Society · doi:10.1021/ja077704u · Cited by 93
Core Binding Factor Acute Myeloid Leukemia
Paschka, P. (2008) · Seminars in Oncology · doi:10.1053/j.seminoncol.2008.04.011 · Cited by 90
Miniature Protein Inhibitors of the p53–hDM2 Interaction
Kritzer, J. A., Zutshi, R., Cheah, M. T., Ran, F. A., Webman, R. B., Wongjirad, T. M., & Schepartz, A. (2006) · ChemBioChem · doi:10.1002/cbic.200500324 · Cited by 90
Natural Product-Based Inhibitors of Hypoxia-Inducible Factor-1 (HIF-1)
Nagle, D. G., & Zhou, Y. (2006) · Current Drug Targets · doi:10.2174/138945006776054979 · Cited by 89
CBP/p300 TAZ1 Domain Forms a Structured Scaffold for Ligand Binding,
Guzman, R. N. D., Wojciak, J. M., Martinez‐Yamout, M. A., Dyson, H. J., & Wright, P. E. (2004) · Biochemistry · doi:10.1021/bi048161t · Cited by 87
Computational Identification of Inhibitors of Protein-Protein Interactions
Zhong, S., Macias, A. T., & MacKerell, A. D. (2006) · Current Topics in Medicinal Chemistry · doi:10.2174/156802607779318334 · Cited by 87
Characterization and prediction of protein–protein interactions within and between complexes
Sprinzak, E., Altuvia, Y., & Margalit, H. (2006) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0603352103 · Cited by 87
Chemical variation of natural product-like scaffolds: design and synthesis of spiroketal derivatives
Zinzalla, G., Milroy, L. ‐., & Ley, S. V. (2006) · Organic & Biomolecular Chemistry · doi:10.1039/b603015g · Cited by 86
Self-citationCell Transduction Pathways of Transportans
Padari, K., Säälik, P., Hansen, M., Koppel, K., Raid, R., Langel, Ü., & Pooga, M. (2005) · Bioconjugate Chemistry · doi:10.1021/bc050125z · Cited by 86
Inhibiting protein–protein interactions using designed molecules
Zhao, L., & Chmielewski, J. A. (2005) · Current Opinion in Structural Biology · doi:10.1016/j.sbi.2005.01.005 · Cited by 84
Selective Inhibition of c‐Myc/Max Dimerization by a Pyrazolo[1,5‐a]pyrimidine
Kiessling, A., Wiesinger, R., Sperl, B., & Berg, T. (2007) · ChemMedChem · doi:10.1002/cmdc.200600294 · Cited by 83
TRANSCRIPTION FACTOR STAT3B/DNA COMPLEX
Becker, S., Groner, B., & Müller, C. W. (1998) · Worldwide Protein Data Bank · doi:10.2210/pdb1bg1/pdb · Cited by 82
Displacement of protein-bound aptamers with small molecules screened by fluorescence polarization
Hafner, M., Vianini, E., Albertoni, B., Marchetti, L., Grüne, I., Gloeckner, C., & Famulok, M. (2008) · Nature Protocols · doi:10.1038/nprot.2008.15 · Cited by 82
The partial retro–inverso modification: A road traveled together
Chorev, M. (2005) · Biopolymers · doi:10.1002/bip.20219 · Cited by 78
Molecular Diversity in Drug Design
Dean, P. M., & Lewis, R. A. (2002) · Kluwer Academic Publishers eBooks · doi:10.1007/0-306-46873-5 · Cited by 77
Ng, P. Y., Tang, Y., Knosp, W. M., Stadler, H. S., & Shaw, J. T. (2007) · Angewandte Chemie International Edition · doi:10.1002/anie.200700762 · Cited by 77
Use of a Retroinverso p53 Peptide as an Inhibitor of MDM2
Sakurai, K., Chung, H. S., & Kahne, D. E. (2004) · Journal of the American Chemical Society · doi:10.1021/ja044883w · Cited by 76
Taylor, S. J., Taylor, A. M., & Schreiber, S. L. (2004) · Angewandte Chemie International Edition · doi:10.1002/anie.200353466 · Cited by 76
Alternate protein frameworks for molecular recognition.
Ku, J., & Schultz, P. G. (1995) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.92.14.6552 · Cited by 74
Solution structure of core binding factor beta and map of the CBF alpha binding site.
Bushweller, J. H., Huang, X., Peng, J. W., & Speck, N. A. (1999) · Nature Structural Biology · doi:10.1038/10670 · Cited by 72
Spatial chemical conservation of hot spot interactions in protein-protein complexes
Shulman‐Peleg, A., Shatsky, M., Nussinov, R., & Wolfson, H. J. (2007) · BMC Biology · doi:10.1186/1741-7007-5-43 · Cited by 72
Small Molecule Modulators of Transcription
Arndt, H. (2006) · Angewandte Chemie International Edition · doi:10.1002/anie.200600285 · Cited by 70
Protein-Protein Interaction Inhibitors: Small Molecules from Screening Techniques
Fletcher, S., & Hamilton, A. J. (2007) · Current Topics in Medicinal Chemistry · doi:10.2174/156802607780906735 · Cited by 69
Altered affinity of CBFβ-SMMHC for Runx1 explains its role in leukemogenesis
Lukasik, S. M., Zhang, L., Corpora, T., Tomanicek, S., Li, Y., Kundu, M., Hartman, K. L., Liu, P., Laue, T. M., Biltonen, R. L., et al. (2002) · Nature Structural Biology · doi:10.1038/nsb831 · Cited by 69
Designing DNA-binding proteins on the surface of filamentous phage
Choo, Y., & Klug, A. (1995) · Current Opinion in Biotechnology · doi:10.1016/0958-1669(95)80073-5 · Cited by 68
Exploiting domino enyne metathesis mechanisms for skeletal diversity generation
Spandl, R. J., Rudyk, H., & Spring, D. R. (2008) · Chemical Communications · doi:10.1039/b807278g · Cited by 66
Paralog-Selective Ligands for Bcl-2 Proteins
Gemperli, A. C., Rutledge, S. E., Maranda, A. M., & Schepartz, A. (2005) · Journal of the American Chemical Society · doi:10.1021/ja0441211 · Cited by 66
Kuroda, J., Kimura, S. H., Strasser, A., Andreeff, M., O’Reilly, L. A., Ashihara, E., Kamitsuji, Y., Yokota, A., Kawata, E., Takeuchi, M., et al. (2007) · Cell Death and Differentiation · doi:10.1038/sj.cdd.4402168 · Cited by 66
The affinity‐selection of a minibody polypeptide inhibitor of human interleukin‐6.
Martin, F., Toniatti, C., Salvati, A. L., Venturini, S., Ciliberto, G., Cortese, R., & Sollazzo, M. (1994) · The EMBO Journal · doi:10.1002/j.1460-2075.1994.tb06864.x · Cited by 65
Exploiting Chemical Diversity for Drug Discovery
(2006) · Royal Society of Chemistry eBooks · doi:10.1039/9781847552556 · Cited by 65
Computationally Designed Peptide Inhibitors of Protein−Protein Interactions in Membranes
Caputo, G. A., Litvinov, R. I., Li, W., BENNETT, J. S., DeGrado, W. F., & Yin, H. H. (2008) · Biochemistry · doi:10.1021/bi800687h · Cited by 64
Mitchell, J. M., & Shaw, J. T. (2006) · Angewandte Chemie International Edition · doi:10.1002/anie.200503341 · Cited by 64
Integration of NMR and High-Throughput Screening
Hajduk, P. J., & Burns, D. J. (2002) · Combinatorial Chemistry & High Throughput Screening · doi:10.2174/1386207023329996 · Cited by 63
Scaffolds for Blocking Protein-Protein Interactions
Hershberger, S. J., Lee, S.-G., & Chmielewski, J. A. (2007) · Current Topics in Medicinal Chemistry · doi:10.2174/156802607780906726 · Cited by 59
Li, Y., Liang, J., Siu, T., Hu, E., Rossi, M., Barnett, S. F., Defeo-Jones, D., Jones, R. E., Robinson, R., Leander, K. R., et al. (2008) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2008.12.017 · Cited by 54
Increasing the Kinase Specificity of K252a by Protein Surface Recognition
Schneider, T. L., Mathew, R. S., Rice, K. P., Tamaki, K., Wood, J. L., & Schepartz, A. (2005) · Organic Letters · doi:10.1021/ol050179o · Cited by 52
Gunning, P. T., Glenn, M. P., Siddiquee, K., Katt, W. P., Masson, E., Sebti, S. M., Turkson, J., & Hamilton, A. D. (2008) · ChemBioChem · doi:10.1002/cbic.200800291 · Cited by 51
Harrison, B. A., Gierasch, T. M., Neilan, C., Pasternak, G. W., & Verdine, G. L. (2002) · Journal of the American Chemical Society · doi:10.1021/ja027150p · Cited by 48
Hämäläinen, M., Zhukov, A., Ivarsson, M., Fex, T., Gottfries, J., Karlsson, R., & Björsne, M. (2008) · SLAS DISCOVERY · doi:10.1177/1087057108314651 · Cited by 47
Targeting the PAS-A Domain of HIF-1α for Development of Small Molecule Inhibitors of HIF-1
Park, J., Kong, D., Fisher, R. J., Cardellina, J. H., Shoemaker, R. H., & Melillo, G. (2006) · Cell Cycle · doi:10.4161/cc.5.16.3019 · Cited by 46
Pescarolo, M. P., Bagnasco, L., Malacarne, D., Melchiori, A., Valente, P., Millo, E., Bruno, S., Basso, S., & Parodi, S. (2000) · The FASEB Journal · doi:10.1096/fj.00-0422fje · Cited by 46
Shultz, M. D., Ham, Y., Lee, S.-G., Davis, D. A., Brown, C. A., & Chmielewski, J. A. (2004) · Journal of the American Chemical Society · doi:10.1021/ja048139n · Cited by 44
Strategies to search and design stabilizers of protein–protein interactions: A feasibility study
Block, P. C., Weskamp, N., Wolf, A., & Klebe, G. (2007) · Proteins Structure Function and Bioinformatics · doi:10.1002/prot.21296 · Cited by 44
Allosteric drugs: thinking outside the active-site box
DeDecker, B. S. (2000) · Chemistry & Biology · doi:10.1016/s1074-5521(00)00115-0 · Cited by 40
Arylamide Derivatives as Peptidomimetic Inhibitors of Calmodulin
Yin, H. H., Frederick, K. K., Liu, D., et al. (2005) · Organic Letters · doi:10.1021/ol052478j · Cited by 39
New Constrained “Molecular Tongs” Designed To Dissociate HIV-1 Protease Dimer
Merabet, N., Dumond, J., Collinet, B., Baelinghem, L. V., Boggetto, N., Ongeri, S., Ressad, F., Reboud‐Ravaux, M., & Sicsic, S. (2004) · Journal of Medicinal Chemistry · doi:10.1021/jm040833q · Cited by 39
Lü, X., Vogt, P. K., Boger, D. L., & Lunec, J. (2008) · Oncology Reports · doi:10.3892/or.19.3.825 · Cited by 39
Three Conformational States of the p300 CH1 Domain Define Its Functional Properties
Dial, R., Sun, Z., & Freedman, S. J. (2003) · Biochemistry · doi:10.1021/bi034989o · Cited by 38
Volkman, H. M., Rutledge, S. E., & Schepartz, A. (2005) · Journal of the American Chemical Society · doi:10.1021/ja042761y · Cited by 35
Chin, J. W., Grotzfeld, R. M., Fabian, M. A., & Schepartz, A. (2001) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/s0960-894x(01)00139-1 · Cited by 34
The application of FAST-NMR for the identification of novel drug discovery targets
Powers, R., Mercier, K., & Copeland, J. C. (2008) · Drug Discovery Today · doi:10.1016/j.drudis.2007.11.001 · Cited by 31
Hintersteiner, M., & Auer, M. (2008) · Annals of the New York Academy of Sciences · doi:10.1196/annals.1430.055 · Cited by 29
Bagnasco, L., Tortolina, L., Biasotti, B., Castagnino, N., Ponassi, R., Tomati, V., Nieddu, E., Stier, G., Malacarne, D., & Parodi, S. (2007) · The FASEB Journal · doi:10.1096/fj.06-7082com · Cited by 28
Protein-Protein Interactions in Drug Discovery
Fischer, P. M. (2005) · Drug Design Reviews - Online · doi:10.2174/1567269053828837 · Cited by 27
Nieddu, E., Melchiori, A., Pescarolo, M. P., Bagnasco, L., Biasotti, B., Licheri, B., Malacarne, D., Tortolina, L., Castagnino, N., Pasa, S., et al. (2005) · The FASEB Journal · doi:10.1096/fj.04-2369fje · Cited by 27
Sioud, M., & Leirdal, M. (2006) · Humana Press eBooks · doi:10.1385/1-59745-208-4:1 · Cited by 20
Cited by
Multifaceted Roles of Disulfide Bonds. Peptides as Therapeutics
Góngora-Benítez, M., Tulla-Puche, J., & Albericio, F. (2014) · Chemical Reviews · doi:10.1021/cr400031z · Cited by 655
Modulators of Protein–Protein Interactions
Milroy, L.-G., Grossmann, T. N., Hennig, S., Brunsveld, L., & Ottmann, C. (2014) · Chemical Reviews · doi:10.1021/cr400698c · Cited by 497
Diversity-oriented synthesis: producing chemical tools for dissecting biology
O' Connor, C. J., Beckmann, H. S. G., & Spring, D. R. (2012) · Chemical Society Reviews · doi:10.1039/c2cs35023h · Cited by 434
Inhibition of Mcl-1 through covalent modification of a noncatalytic lysine side chain
Akçay, G., Belmonte, M. A., Aquila, B., Chuaqui, C., Hird, A. W., Lamb, M. L., Rawlins, P. B., Su, N., Tentarelli, S., Grimster, N. P., et al. (2016) · Nature Chemical Biology · doi:10.1038/nchembio.2174 · Cited by 207
State-of-the-art strategies for targeting protein–protein interactions by small-molecule inhibitors
Sheng, C., Dong, G., Miao, Z., Zhang, W., & Wang, W. (2015) · Chemical Society Reviews · doi:10.1039/c5cs00252d · Cited by 165
Metadata
- Authors
- Zinzalla, G., & Thurston, D. E.
- Venue
- Future Medicinal Chemistry
- Publisher
- Informa UK Limited
- Published
- 2009-04
- Volume
- 1
- Issue
- 1
- Pages
- 65-93
- ISSN
- 1756-8919 (ISSN-L)
- 1756-8927
- OpenAlex
- W2106060578
- Cited by
- 260
- References
- 210
- FWCI
- 3.72
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.